Improving Pharmacist Knowledge of Oral Chemotherapy in the Community

Charpentier, Margaret M.; Orr, Katherine Kelly; Taveira, Tracey H.

doi:10.1345/aph.1r056

Cited by 21 publications

(14 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[9][10][11] Several cancer centers in large academic medical centers in the United States have shown data to support the value of oncology-trained clinical pharmacist-driven interventions to enhance the care of patients on oral chemotherapy. [12][13][14][15][16] Added value includes improved medication adherence, decreased significant drug-related interactions and toxicities, and enhanced overall patient satisfaction. Institution-based data at the Cone Health Cancer Center in Greensboro, North Carolina showed adherence rates of 86% to 92% in patients who received pharmacist intervention on oral chemotherapy, as well as an increase in physician and patient satisfaction scores.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the prescribing patterns, adverse effects, and drug interactions of oral chemotherapy agents in an outpatient cancer center

Solomon

Ajewole

Schneider

et al. 2018

J Oncol Pharm Pract

View full text Add to dashboard Cite

Purpose Although oral chemotherapy offers advantages over intravenous chemotherapy, it creates a unique set of challenges. Potential barriers include treatment complexity, patient responsibility for medication adherence and monitoring, reduced healthcare contact, and increased financial burden. The purpose of this study is to estimate the prevalence of drug-related problems among a sample of patients treated with oral chemotherapy agents. Methods A single-center, retrospective chart review was conducted on patients prescribed oral chemotherapy at our institution between 1 January 2017 and 31 August 2017. The primary endpoint was the incidence of drug-related toxicities within 90 days of starting treatment. Secondary endpoints included incidence of drug-drug interactions, proportion of patients receiving medication education by a clinical pharmacist, and quantification of issues related to medication access. Results Charts of 100 patients were reviewed. Median time to oral chemotherapy receipt by the patient from the day the order was written was eight days. Prior to initiating therapy, 27% of patients received education by a clinical pharmacist. Toxicity checks were conducted by the provider at 30, 60, and 90 days for 80%, 65%, and 48% of patients, respectively. Treatment-related toxicities secondary to oral chemotherapy were reported by 79% of patients, with 55% classified as severe. Potential drug interactions were in 55% of the patients. Conclusion Data from this study have highlighted avenues for pharmacists to make an impact on patients newly started on oral chemotherapy. Opportunities exist to increase patient education, ensure appropriate follow-up, and assess adherence while preventing and managing treatment-related toxicities.

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of the prescribing patterns, adverse effects, and drug interactions of oral chemotherapy agents in an outpatient cancer center

Solomon

Ajewole

Schneider

et al. 2018

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“…In spite of the risks and challenges associated with oral chemotherapy drugs, their use is likely to become more prevalent. In 2012, about 10% of all chemotherapy was given in oral form, and the use is expected to increase (Charpentier, Orr, & Taveira, 2012;Yagasaki & Komatsu, 2013). In addition, many patients prefer oral drugs over parenteral ones, even if they erroneously believe that the oral drugs are less effective (Findlay, von Minckwitz, & Wardley, 2008;Palmieri & Barton, 2007).…”

Section: Resultsmentioning

confidence: 99%

Current Practice Patterns for Oral Chemotherapy: Results of a National Survey

Roop¹,

Wu²

2013

Oncology Nursing Forum

View full text Add to dashboard Cite

show abstract

“…These results compare similarly to those of other authors where a high knowledge score was attained post completion of a targeted continuing pharmacy education program. (Charpentier et al 2012 ).…”

Section: Discussionmentioning

confidence: 99%

The impact of a pilot continuing professional development module on hospital pharmacists’ preparedness to provide contemporary advice on the clinical use of vancomycin

et al. 2016

View full text Add to dashboard Cite

BackgroundRevised international clinical guidelines for the antibiotic vancomycin have changed the advice pharmacists need to provide to medical and nursing colleagues.Objectives(1) To determine the self-reported confidence of hospital pharmacists to provide contemporary advice on vancomycin and (2) to evaluate hospital pharmacists’ knowledge to provide contemporary advice on vancomycin following a pilot continuing professional development (CPD) module.MethodsThe study was a prospective two-phase design in an Australian teaching hospital. Phase one: a survey of pharmacist self-reported confidence to eight questions on providing contemporary advice on vancomycin. Responses were recorded using a Likert scales. Phase two: The provision of a pilot online CPD module on vancomycin containing knowledge-based assessment based on a clinical vignette. Likert scales recorded self-reported confidence were reported as median and interquartile range (IQR). Knowledge assessment was reported using descriptive statistics. The main outcome measure were the self-reported confidence, and knowledge of pharmacists regarding provision of contemporary advice on clinical vancomycin use.ResultsResponse rates for surveys; confidence n = 35 (72.9 %) and knowledge n = 31 (58.5 %). Phase one: confidence was highest regarding vancomycin dosing and monitoring with 71.4–81.6 % of respondents agreeing or strongly agreeing that they were confident in these domains. Respondents agreeing or strongly agreeing were least confident regarding intravenous administration and infusion related reactions, 57.1 and 45.7 % respectively. Respondents who provided advice on vancomycin >10 times in the prior 12 months reported significantly higher confidence in; therapeutic range 1 (IQR 1–2) versus 2 (IQR 1–3) p = 0.02; amending dosage based on therapeutic drug monitoring results 2 (IQR 1–3) versus 3 (IQR 2–3) p = <0.001, and providing general advice to prescribers on vancomycin 2 (IQR 1–3) versus 2 (IQR 2–4) p = <0.009. Knowledge questions were answered correctly post CPD by >75 % of pharmacists.ConclusionPharmacists’ self-reported confidence to managing vancomycin was variable but generally high. Knowledge scores were consistently high after pharmacists completed a pilot CPD module on vancomycin. These data provides impetus for a randomised controlled study across multiple sites to determine the extent to which pharmacist knowledge on vancomycin can be attributed to completion of an online CPD.Electronic supplementary materialThe online version of this article (doi:10.1186/s40064-016-1966-2) contains supplementary material, which is available to authorized users.

show abstract

Improving Pharmacist Knowledge of Oral Chemotherapy in the Community

Cited by 21 publications

References 10 publications

Evaluation of the prescribing patterns, adverse effects, and drug interactions of oral chemotherapy agents in an outpatient cancer center

Evaluation of the prescribing patterns, adverse effects, and drug interactions of oral chemotherapy agents in an outpatient cancer center

Current Practice Patterns for Oral Chemotherapy: Results of a National Survey

The impact of a pilot continuing professional development module on hospital pharmacists’ preparedness to provide contemporary advice on the clinical use of vancomycin

Contact Info

Product

Resources

About